Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp
- PMID: 22473914
- PMCID: PMC3525944
- DOI: 10.1002/cmdc.201100600
Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp
Abstract
Two voltage-dependent potassium channels, Kv1.1 (KCNA1) and Kv1.2 (KCNA2), are found to co-localize at the juxtaparanodal region of axons throughout the nervous system and are known to co-assemble in heteromultimeric channels, most likely in the form of the concatemer Kv1.1-1.2((3)) . Loss of the myelin sheath, as is observed in multiple sclerosis, uncovers the juxtaparanodal region of nodes of Ranvier in myelinated axons leading to potassium conductance, resulting in loss of nerve conduction. The selective blocking of these Kv channels is therefore a promising approach to restore nerve conduction and function. In the present study, we searched for novel inhibitors of Kv1.1-1.2((3)) by combining a virtual screening protocol and electrophysiological measurements on a concatemer Kv1.1-1.2((3)) stably expressed in Chinese hamster ovary K1 (CHO-K1) cells. The combined use of four popular virtual screening approaches (eHiTS, FlexX, Glide, and Autodock-Vina) led to the identification of several compounds as potential inhibitors of the Kv1.1-1.2((3)) channel. From 89 electrophysiologically evaluated compounds, 14 novel compounds were found to inhibit the current carried by Kv1.1-1.2((3)) channels by more than 80 % at 10 μM. Accordingly, the IC(50) values calculated from concentration-response curve titrations ranged from 0.6 to 6 μM. Two of these compounds exhibited at least 30-fold higher potency in inhibition of Kv1.1-1.2((3)) than they showed in inhibition of a set of cardiac ion channels (hERG, Nav1.5, and Cav1.2), resulting in a profile of selectivity and cardiac safety. The results presented herein provide a promising basis for the development of novel selective ion channel inhibitors, with a dramatically lower demand in terms of experimental time, effort, and cost than a sole high-throughput screening approach of large compound libraries.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figures



Similar articles
-
A new Kaliotoxin selective towards Kv1.3 and Kv1.2 but not Kv1.1 channels expressed in oocytes.Biochem Biophys Res Commun. 2008 Nov 21;376(3):525-30. doi: 10.1016/j.bbrc.2008.09.033. Epub 2008 Sep 18. Biochem Biophys Res Commun. 2008. PMID: 18804453
-
KV1.2 channel-specific blocker from Mesobuthus eupeus scorpion venom: Structural basis of selectivity.Neuropharmacology. 2018 Dec;143:228-238. doi: 10.1016/j.neuropharm.2018.09.030. Epub 2018 Sep 22. Neuropharmacology. 2018. PMID: 30248306
-
High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay.J Biomol Screen. 2010 Feb;15(2):185-95. doi: 10.1177/1087057109356209. Epub 2009 Dec 31. J Biomol Screen. 2010. PMID: 20044579
-
Novel screening techniques for ion channel targeting drugs.Channels (Austin). 2015;9(6):367-75. doi: 10.1080/19336950.2015.1079675. Epub 2015 Nov 10. Channels (Austin). 2015. PMID: 26556400 Free PMC article. Review.
-
Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5.Biomolecules. 2019 Dec 19;10(1):10. doi: 10.3390/biom10010010. Biomolecules. 2019. PMID: 31861703 Free PMC article. Review.
Cited by
-
Targeting ion channels with ultra-large library screening for hit discovery.Front Mol Neurosci. 2024 Jan 5;16:1336004. doi: 10.3389/fnmol.2023.1336004. eCollection 2023. Front Mol Neurosci. 2024. PMID: 38249296 Free PMC article. Review.
-
Kv1.1 Channelopathies: Pathophysiological Mechanisms and Therapeutic Approaches.Int J Mol Sci. 2020 Apr 22;21(8):2935. doi: 10.3390/ijms21082935. Int J Mol Sci. 2020. PMID: 32331416 Free PMC article. Review.
-
Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease.PLoS Genet. 2019 Jun 6;15(6):e1008180. doi: 10.1371/journal.pgen.1008180. eCollection 2019 Jun. PLoS Genet. 2019. PMID: 31170158 Free PMC article.
-
A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine.Int J Mol Sci. 2021 Sep 14;22(18):9913. doi: 10.3390/ijms22189913. Int J Mol Sci. 2021. PMID: 34576077 Free PMC article.
-
Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.FASEB J. 2018 Feb;32(2):1025-1043. doi: 10.1096/fj.201700182RRR. Epub 2018 Jan 3. FASEB J. 2018. PMID: 29097503 Free PMC article.
References
-
- Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR. Ann. Neurol. 2010;68:494–502. - PubMed
-
- Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR. Lancet. 2009;373:732–738. - PubMed
-
- Rajakulendran S, Schorge S, Kullmann D, Hanna M. Neurotherapeutics. 2007;4:258–266. - PubMed
-
- Coleman SK, Newcombe J, Pryke J, Dolly JO. J. Neurochem. 1999;73:849–858. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources